Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database
- 13 April 2026
- journal article
- research article
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (4) , 563-567
Abstract
Anti–tumor necrosis factor (TNF) agents are widely used for inflammatory bowel disease and have well-documented heart failure risk, but comparative cardiac safety remains uncertain. We conducted a retrospective cohort study using the TriNetX US national database. Adults with Crohn’s disease or ulcerative colitis initiating infliximab or adalimumab were included. Patients with prior heart failure were excluded. The primary outcome was heart failure occurring ≥ 6 months after anti-TNF initiation. Propensity score matching was performed to balance baseline covariates. Before matching, 25,582 patients received infliximab and 24,301 received adalimumab. After matching, 21,554 remained in each group. Median follow-up was ≈ 3.65 years (infliximab) and ≈ 3.91 years (adalimumab). Heart failure occurred in 466 (2.21%) infliximab patients vs 383 (1.81%) adalimumab patients (risk ratio, 1.22; 95% confidence interval [CI] 1.068–1.395; P = 0.003). In an exploratory Cox model, infliximab was associated with a higher heart failure hazard, 1.179 (95% CI 1.029–1.35), and a significant Kaplan-Meier curve by log-rank test (P = 0.02). In this national database analysis of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of incident heart failure compared with adalimumab.Keywords
This publication has 19 references indexed in Scilit:
- Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized studyArthritis & Rheumatism, 2012
- Neutropenia in patients receiving anti–tumor necrosis factor therapyArthritis Care & Research, 2010
- Biological Therapies for Inflammatory Bowel DiseasesGastroenterology, 2009
- Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitaskerDigestive and Liver Disease, 2008
- Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF- antagonistsRheumatology, 2007
- Tumor Necrosis Factor Blockade: Mechanism of ActionJournal of Investigative Dermatology Symposium Proceedings, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997